Protein transduction domains: Applications for molecular medicine

Current Gene Therapy

Volumn 12, Issue 5, 2012, Pages 374-380

  Zahid, Maliha ^a,b   Robbins, Paul D ^c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Excela Health Cardiology   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Gene delivery; Imaging; NF B; Protein transduction domains

Indexed keywords

ADENOVIRUS VECTOR; ANTENNAPEDIA PROTEIN; CELL PENETRATING PEPTIDE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; QUANTUM DOT; SMALL INTERFERING RNA; TECHNETIUM; THALLIUM; TRANSACTIVATOR PROTEIN;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CELL MEMBRANE PERMEABILITY; COMBINATORIAL LIBRARY; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PHAGE DISPLAY; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSDUCTION DOMAIN; REVIEW; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; MOLECULAR MEDICINE; OLIGOPEPTIDES; OPTICAL IMAGING; ORGAN SPECIFICITY; PROTEIN TRANSPORT;

EID: 84866996099     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652312802762527     Document Type: Review

References (50)

1. Green M, Loewenstein PM. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat transactivator protein. Cell 1988; 55(6):1179-88.
2. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55(6):1189-93.
3. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci U S A 1994; 91(2):664-8.
4. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999; 285(5433):1569-72.
5. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci U S A 1991; 88(5):1864-8.
6. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci U S A 2000; 97(24):13003-8.
7. Mai JC, Shen H, Watkins SC, Cheng T, Robbins PD. Efficiency of protein transduction is cell type-dependent and is enhanced by dextran sulfate. J Biol Chem 2002; 277(33):30208-18.
8. El-Andaloussi S, Johansson H, Magnusdottir A, Jarver P, Lundberg P, Langel U. TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J Control Release 2005; 110(1):189-201.
9. Rusnati M, Coltrini D, Oreste P, Zoppetti G, Albini A, Noonan D, et al. Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J Biol Chem 1997; 272(17):11313-20.
10. Tyagi M, Rusnati M, Presta M, Giacca M. Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. J Biol Chem 2001; 276(5):3254-61.
11. Li Y, Rosal RV, Brandt-Rauf PW, Fine RL. Correlation between hydrophobic properties and efficiency of carrier-mediated membrane transduction and apoptosis of a p53 C-terminal peptide. Biochem Biophys Res Commun 2002; 298(3):439-49.
12. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279(5349):377-80.
13. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102(2):231-7.
14. Mi Z, Lu X, Mai JC, Ng BG, Wang G, Lechman ER, et al. Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium. Mol Ther 2003; 8(2):295-305.
15. Chamarthy SP, Jia L, Kovacs JR, Anderson KR, Shen H, Firestine SM, et al. Gene delivery to dendritic cells facilitated by a tumor necrosis factor alpha-competing peptide. Molecular immunology 2004; 41(8):741-9.
16. Rehman KK, Bertera S, Bottino R, Balamurugan AN, Mai JC, Mi Z, et al. Protection of islets by in situ peptide-mediated transduction of the Ikappa B kinase inhibitor Nemo-binding domain peptide. J Biol Chem 2003; 278(11):9862-8.
17. Zahid M, Phillips BE, Albers SM, Giannoukakis N, Watkins SC, Robbins PD. Identification of a cardiac specific protein transduction domain by in vivo biopanning using a M13 phage peptide display library in mice. PLoS One 2010; 5(8):e12252.
18. Zahid M, Robbins PD. Identification and characterization of tissuespecific protein transduction domains using peptide phage display. Methods Mol Biol. 2011; 683:277-89.
19. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV proteaseactivated caspase-3 protein. Nat Med 1999; 5(1):29-33.
20. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res 2002; 62(7):2013-8.
21. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nature reviews Immunology 2005; 5(10):749-59.
22. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nature reviews Cancer 2002; 2(4):301-10.
23. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 2000; 289(5484):1550-4.
24. Tas SW, Vervoordeldonk MJ, Tak PP. Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 2009; 9(3):160-70.
25. Reay DP, Yang M, Watchko JF, Daood M, O'Day TL, Rehman KK, et al. Systemic delivery of NEMO binding domain/ IKKgamma inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiol Dis 2011; 43(3):598-608.
26. Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfin DA, et al. Peptide-based inhibition of NF-kappaB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med 2011; 17(5-6):508-15.
27. Delfin DA, Xu Y, Peterson JM, Guttridge DC, Rafael-Fortney JA, Janssen PM. Improvement of cardiac contractile function by peptide-based inhibition of NF-kappaB in the utrophin/dystrophindeficient murine model of muscular dystrophy. J Transl Med 2011; 9:68.
28. Dave SH, Tilstra JS, Matsuoka K, Li F, Karrasch T, Uno JK, et al. Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol 2007; 179(11):7852-9.
29. Katterle Y, Brandt BH, Dowdy SF, Niggemann B, Zanker KS, Dittmar T. Antitumour effects of PLC-gamma1-(SH2)2-TAT fusion proteins on EGFR/c-erbB-2-positive breast cancer cells. Brit J Cancer 2004; 90(1):230-5.
30. Takenobu T, Tomizawa K, Matsushita M, Li ST, Moriwaki A, Lu YF, et al. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol Cancer Ther 2002; 1(12):1043-9.
31. Michiue H, Tomizawa K, Wei FY, Matsushita M, Lu YF, Ichikawa T, et al. The NH2 terminus of influenza virus hemagglutinin-2 subunit peptides enhances the antitumor potency of polyargininemediated p53 protein transduction. J Biol Chem 2005; 280(9):8285-9.
32. Araki D, Takayama K, Inoue M, Watanabe T, Kumon H, Futaki S, et al. Cell-penetrating D-isomer peptides of p53 C-terminus: longterm inhibitory effect on the growth of bladder cancer. Urology 2010; 75(4):813-9.
33. Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, et al. TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 2007; 14(5):1763-71.
34. Kwon MK, Nam JO, Park RW, Lee BH, Park JY, Byun YR, et al. Antitumor effect of a transducible fusogenic peptide releasing multiple proapoptotic peptides by caspase-3. Mol Cancer Ther 2008; 7(6):1514-22.
35. Kim HY, Kim S, Youn H, Chung JK, Shin DH, Lee K. The cell penetrating ability of the proapoptotic peptide, KLAKLAKKLAKLAK fused to the N-terminal protein transduction domain of translationally controlled tumor protein, MIIYRDLISH. Biomaterials 2011; 32(22):5262-8.
36. Nguyen QT, Olson ES, Aguilera TA, Jiang T, Scadeng M, Ellies LG, et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A 2010; 107(9):4317-22.
37. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, et al. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A 2010; 107(9):4311-6.
38. Ruan G, Agrawal A, Marcus AI, Nie S. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc 2007; 129(47):14759-66.
39. Lei Y, Tang H, Yao L, Yu R, Feng M, Zou B. Applications of mesenchymal stem cells labeled with Tat peptide conjugated quantum dots to cell tracking in mouse body. Bioconjug Chem 2008; 19(2):421-7.
40. Xu Y, Liu BR, Lee HJ, Shannon KB, Winiarz JG, Wang TC, et al. Nona-arginine facilitates delivery of quantum dots into cells via multiple pathways. J Biomed Biotechnol 2010; 2010:948543.
41. Prantner AM, Sharma V, Garbow JR, Piwnica-Worms D. Synthesis and characterization of a Gd-DOTA-D-permeation peptide for magnetic resonance relaxation enhancement of intracellular targets. Mol Imaging 2003; 2(4):333-41.
42. Schott JW, Galla M, Godinho T, Baum C, Schambach A. Viral and non-viral approaches for transient delivery of mRNA and proteins. Curr Gene Ther 2011; 11(5):382-98.
43. Gratton JP, Yu J, Griffith JW, Babbitt RW, Scotland RS, Hickey R, et al. Cell-permeable peptides improve cellular uptake and therapeutic gene delivery of replication-deficient viruses in cells and in vivo. Nat Med 2003; 9(3):357-62.
44. Eto Y, Yoshioka Y, Asavatanabodee R, Kida S, Maeda M, Mukai Y, et al. Transduction of adenovirus vectors modified with cellpenetrating peptides. Peptides 2009; 30(8):1548-52.
45. Youn JI, Park SH, Jin HT, Lee CG, Seo SH, Song MY, et al. Enhanced delivery efficiency of recombinant adenovirus into tumor and mesenchymal stem cells by a novel PTD. Cancer Gene Ther 2008; 15(11):703-12.
46. Rajagopalan R, Xavier J, Rangaraj N, Rao NM, Gopal V. Recombinant fusion proteins TAT-Mu, Mu and Mu-Mu mediate efficient non-viral gene delivery. J Gene Med 2007; 9(4):275-86.
47. Tiera MJ, Shi Q, Winnik FM, Fernandes JC. Polycation-based gene therapy: current knowledge and new perspectives. Curr Gene Ther 2011; 11(4):288-306.
48. Ezzat K, Zaghloul EM, El Andaloussi S, Lehto T, El-Sayed R, Magdy T, et al. Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions. J Control Release 2012; 162(1):1-8.
49. Cheng CJ, Saltzman WM. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol Pharm 2012; 9(5):1481-8.
50. Gabrielson NP, Lu H, Yin L, Kim KH, Cheng J. A Cell-penetrating Helical Polymer For siRNA Delivery to Mammalian Cells. Mol Ther 2012; 29.